Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Adams, Buin ^a   Mapanga, Rudo F ^a   Essop, M Faadiel ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Autophagy; Cardiac dysfunction; Hyperglycemia; Inflammation; Ischemia reperfusion; Oxidative stress; Ubiquitin proteasome system

Indexed keywords

ATROGIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOSE; I KAPPA B KINASE ALPHA; LACTACYSTIN; MANGANESE SUPEROXIDE DISMUTASE; MICROTUBULE ASSOCIATED PROTEIN 1; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P62; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; LEUPEPTIN; SOD1 PROTEIN, RAT; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOPHAGY; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERGLYCEMIA; MALE; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TREATMENT DURATION; UBIQUITIN PROTEASOME SYSTEM; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CARDIAC MUSCLE; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; ENZYMOLOGY; ISOLATED HEART; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; WISTAR RAT;

ACETYLCYSTEINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; AUTOPHAGY; DIABETIC CARDIOMYOPATHIES; HYPERGLYCEMIA; INFLAMMATION MEDIATORS; ISOLATED HEART PREPARATION; LEUPEPTINS; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEASOME INHIBITORS; RATS, WISTAR; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE-1; TIME FACTORS;

EID: 84937960951     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0258-4     Document Type: Article

References (54)

1. Soedamah-Muthu S, Fuller J, Mulnier HE, Raleigh VS, Lawrenson R, Colhoun HM (2006) High risk of cardiovascular disease in a cohort study using the General Practice Research Database. Diabetes Care 29:798-804
2. Gardner A (2014) The benefits of tight glycemic control in critical illness: sweeter than assumed? Indian J Crit Care Med 18(12):807
3. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Cañizo-Gómez FJ (2014) Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes 5(4):444-470
4. Marcovecchio ML, Lucantoni M, Chiarelli F (2011) Role of chronic and cute hyperglycemia in the development of diabetes complications. Diabetes Technol Ther 13:389-394
5. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with T2DM (UKPDS 33). Lancet 352:837-845
6. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
7. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29-34
8. Capes SE, Hunt D, Malmberg K, Gerstein HC (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773-778
9. Marfella R, Di Filippo C, Portoghese M, Ferraraccio F, Rizzo MR, Siniscalchi M et al (2009) Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol 53(16):1425-1436
10. Sleiman I, Morandi A, Sabatini T, Ranhoff A, Ricci A, Rozzini R et al (2008) Hyperglycemia as a predictor of in-hospital mortality in elderly patients without diabetes mellitus admitted to a sub-intensive care unit. J Am Geriatr Soc 56(6):1106-1110
11. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L et al (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140-2144
12. Sawin G, Shaughnessy AF (2010) Glucose control in hospitalized patients. Am Fam Physician 81(9):1121-1124
13. Powell SR (2006) The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 291:H1-H19
14. Kriegenburg F, Ellgaard L, Hartmann-Petersen R (2012) Molecular chaperones in targeting misfolded proteins for ubiquitin-dependent degradation. FEBS J 279(4):532-542
15. Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y et al (2013) Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB. Am J Physiol Heart Circ Physiol 304(4):H567-H578
16. Marfella R, Di C, Portoghese M, Siniscalchi M, Martis S, Ferraraccio F et al (2009) The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol 18(6):332-345
17. Huang S, Patterson E, Yu X, Garrett MW, De Aos I, Kem DC (2008) Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol 294(3):H1298-H1303
18. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B et al (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276(32):30057-30063
19. Zolk O, Schenke C, Sarikas A (2006) The ubiquitin-proteasome system: focus on the heart. Cardiovasc Res 70(3):410-421
20. Calise J, Powell SR (2013) The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol 304(3):H337-H349
21. Mapanga R, Rajamani U, Dlamini N, Zungu-Edmondson M, Kelly-Laubscher R, Shafiullah M et al (2012) Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. PLoS One 7(10):e47322
22. Mapanga RF, Joseph D, Symington B, Garson K-L, Kimar C, Kelly-Laubscher R et al (2014) Detrimental effects of acute hyperglycaemia on the rat heart. Acta Physiol (Oxf) 210:546-564
23. Harris F, Pierpoint L (2012) Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 32(6):1292-1327
24. Fenteany G, Standaert R, Lane W, Choi S, Corey E, Schreiber S (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731
25. Borissenko L, Groll M (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107(3):687-717
26. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL et al (1997) Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272(20):13437-13445
27. Divald A, Powell SR (2006) Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med 40:156-164
28. Powell S, Wang P, Katzeff H, Shringarpure R, Teoh C, Khaliulin I et al (2005) Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal 7:538-546
29. Rajamani U, Joseph D, Roux S, Essop MF (2011) The hexosamine biosynthetic pathway can mediate myocardial apoptosis in a rat model of diet-induced insulin resistance. Acta Physiol (Oxf) 202(2):151-157
30. Rajamani U, Essop MF (2010) Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am J Physiol Cell Physiol 299(1):C139-C147
31. Yu X, Kem DC (2010) Proteasome inhibition during myocardial infarction. Cardiovasc Res 85:312-320
32. Campbell B, Adams J, Shin Y, Lefer A (1999) Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31:467-476
33. Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J et al (2003) Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284(3):H919-H926
34. Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH (2007) Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg 84(1):120-125
35. Wang X, Robbins J (2014) Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol 71:16-24
36. Tian Z, Zheng H, Li J, Li Y, Su H, Wang X (2012) Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in Mice. Circ Res 111(5):532-542
37. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8(8):739-758
38. Ma Y, Chen B, Liu D, Yang Y, Xiong Z, Zeng J et al (2011) MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κβ/TGFβ1 pathway. Biochem Pharmacol 81(10):1228-1236
39. Stangl K, Günther C, Frank T, Lorenz M, Meiners S, Röpke T et al (2002) Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem Biophys Res Commun 291:542-549
40. Kassiotis C, Rajabi M, Taegtmeyer H (2008) Metabolic reserve of the heart: the forgotten link between contraction and coronary flow. Prog Cardiovasc Dis 51(1):74-88
41. Buja LM, Entman ML (1998) Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 98(14):1355-1357
42. Murriel CL, Churchill E, Inagaki K, Szweda LI, Mochly-Rosen D (2004) Protein kinase C delta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J Biol Chem 279(46):47985-47991
43. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625
44. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B et al (1997) Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 40:647-653
45. Rösen P, Du X, Tschöpe D (1998) Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention with alpha tocopherol? Mol Cell Biochem 188:103-111
46. Holtzclaw WD, Dinkova-Kostova AT, Talalay P (2004) Protection against electrophile and oxidative stress by induction of phase 2 genes: the quest for the elusive sensor that responds to inducers. Adv Enzyme Regul 44:335-367
47. Kobayashi A, Ohta T, Yamamoto M (2000) Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol 2004(378):273-286
48. McMahon M, Itoh K, Yamamoto M, Hayes JD (2003) Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278(24):21592-21600
49. Kobayashi A, Kang M, Okawa H, Zenke Y, Chiba T, Igarashi K et al (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24(16):7130-7139
50. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M (2005) Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280(34):30091-30099
51. Willis MS, Townley-Tilson WHD, Kang EY, Homeister JW, Patterson C (2010) Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 106(3):463-478
52. Korolchuk VI, Menzies FM, Rubinsztein DC (2010) Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584(7):1393-1398
53. Zheng Q, Su H, Tian Z, Wang X (2011) Proteasome malfunction activates macroautophagy in the heart. Am J Cardiovasc Dis 1(3):214-226
54. Wang B, Yang Q, Sun YY, Xing YF, Bin WY, Lu XT et al (2014) Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med 18(8):1599-1611